Clinical trials: sponsored by Genentech, Inc.
Asthma
A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
This was a multicenter, parallel-group, double-blind, randomized, placebo-controlled study that enrolled 333 subjects. These subjects were 12-75 years old with atopic asthma, had elevated serum total Immunoglobulin E (IgE), had a…
- Trial name
- EXACT (NCT00096954)
- Testing
- omalizumab (Xolair)
- Volunteers
- 333 people
- Sponsor
- Genentech, Inc.
Healthy, Asthma
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
This study enrolled 30 healthy volunteers and 30 patients with atopic asthma, for a total of 60 subjects. The study examined the tolerability of omalizumab and omalizumab excipients in two successive cohorts of subjects, healthy…
- Trial name
- NCT00777764
- Testing
- Cohort I, Cohort 2
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Chronic Rhinosinusitis, Nasal Polyps
Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis
The investigators are doing this research study to learn more about a drug called Xolair (omalizumab). The investigators want to see if it is an effective treatment for chronic rhinosinusitis (CRS).
- Trial name
- NCT01066104
- Testing
- Xolair (omalizumab)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or…
- Trial name
- AMBER (NCT00473590)
- Testing
- Bevacizumab, Bortezomib
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Adenocarcinoma
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or…
- Trial name
- AVAGAST (NCT00548548)
- Testing
- Bevacizumab, Capecitabine, Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 774 people
- Sponsor
- Genentech, Inc.
B-cell Lymphoma, Indolent B-cell Lymphoma
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
The purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas.
- Trial name
- NCT00895661
- Testing
- rituximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Metastatic Colorectal Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression.
- Trial name
- NCT00636610
- Testing
- Vismodegib 150 mg, Bevacizumab, Modified FOLFOX
- Volunteers
- 199 people
- Sponsor
- Genentech, Inc.
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
The study was a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of vismodegib (GDC-0449) in patients with ovarian cancer in a second or third complete remission.
- Trial name
- NCT00739661
- Testing
- Vismodegib 150 mg
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer, Ovarian Cancer
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A administered as a single agent by intravenous (IV) infusion every three weeks (q3w) to participants with non-squamous NSCLC or non-mucinous…
- Trial name
- NCT01363947
- Testing
- DNIB0600A
- Where
- 7 sites in United States, Spain
- Volunteers
- 87 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has…
- Trial name
- NCT00517049
- Testing
- PRO95780, rituximab
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque…
- Trial name
- SCALP (NCT00669214)
- Testing
- efalizumab
- Volunteers
- 89 people
- Sponsor
- Genentech, Inc.
Growth Hormone Deficiency
National Cooperative Growth Study in CKD
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.
- Trial name
- NCGS (NCT00616278)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis
Healthy Volunteer
A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
This Phase I, single-dose, randomized, parallel-group, open-label study will evaluate the safety, tolerability, and pharmacokinetics of MABT5102A following subcutaneous (SC) and intravenous (IV) administration in healthy…
- Trial name
- NCT00997919
- Testing
- MABT5102A
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Colorectal Cancer
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT01418222
- Testing
- 5-FU, FOLFOX regimen, bevacizumab [Avastin]
- Where
- 23 sites in United States
- Volunteers
- 194 people
- Sponsor
- Genentech, Inc.
Cancer
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
This is a phase II study designed to study the effectiveness of combined radiotherapy and erlotinib in the postoperative setting for patients with cutaneous SCC that are at high risk for recurrence.
- Trial name
- RAD0503 (NCT00369512)
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Brain Cancer, Recurrent Malignant Gliomas
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted.
- Conditions
- Brain Cancer, Recurrent Malignant Gliomas, Primary Brain Tumor
- Trial name
- NCT00595322
- Testing
- bevacizumab and radiation (IMRT)
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft Versus Host Disease
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
RATIONALE: Efalizumab may be an effective treatment for graft-versus-host disease of the skin caused by a donor stem cell transplant.
- Trial name
- NRR (NCT00489216)
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center